Grünenthal is a global leader in pain management and related diseases. As a science-based, privately-owned pharmaceutical company, we have a long track record of bringing innovative treatments and state-of-the-art technologies to patients worldwide. Our purpose is to change lives for the better, and innovation is our passion. We are focusing all our activities and efforts on working towards our vision of a world free of pain.
4,400 Grünenthal employees worldwide join forces every day to drive progress towards our vision of a World Free of Pain. Together, we achieved record revenues in 2023. And our scientists made important progress with developing innovative medicines for pain patients.
Our most recent report shares information about our company’s strategy, highlight projects and financial performance.
Our commitment to the PSCI
Grünenthal is a member of the Pharmaceutical Supply Chain Initiative (PSCI) (https://pscinitiative.org/home). This global movement is driving positive change in our industry through collaboration to promote more responsible and sustainable practices along the entire value chain. It brings together pharma companies, suppliers and other stakeholders with the shared mission of promoting progress. By working together, we aim to ensure access to safe and reliable medicines for patients worldwide.
Find more information about Grünenthal’s commitment to responsible sourcing here.The U.S. Food and Drug Administration (FDA) has granted breakthrough therapy designation to resiniferatoxin for pain associated with knee osteoarthritis (OA). The investigational, non-opioid medicine is currently in Phase III clinical development.
Knee OA affects more than 360 million people worldwide. Patients often experience severe pain, and many are impacted in their daily activities. If approved, resiniferatoxin could become a meaningful treatment option providing long-lasting pain relief and functional improvement of the affected joint.
Learn more about our asset and how it may address one of the most common and severe symptoms in knee OA
Download PR FDA Breakthrough Therapy Designation for Grünenthal’s resiniferatoxin
Working at Grünenthal means experiencing the impact you can have on the results we achieve and the lives of the patients we serve.
Join forces.
Make an impact.
Innovate for a world free of pain.
